

Evolution Research Group 430 Mountain Avenue, Suite 302 New Providence, NJ 07974 www.ergclinical.com Office: 908.756.4411 | Fax: 908.756.1122 Email: info@ergclinical.com

Stable Schizophrenia Phase 1b Case Study

An Open-Label, Parallel-Arm, Two-Period, Single-Dose Pilot Study to Assess the Pharmacokinetics and the Effect of Food on the Pharmacokinetics of Five Once Weekly Oral Formulations of XXXXX in Adult Subjects with Schizophrenia

St. Louis Clinical Trials

Phase: 1b Indication: Schizophrenia (Stable) # of Subjects: 30 Randomized Inpatient Period: 28 days

OBJECTIVES

Primary

Pharmacokinetics of XXXXX and its metabolite in plasma following administration of once weekly XXXXX tablets in the fasted state and after a high fat meal.

Secondary

Safety and tolerability of XXXXX following administration of once weekly XXXXX

Ratings

Abnormal Involuntary Movement Scale (AIMS) Simpson-Angus Neurologic Rating Scale (SAS) Barnes-Akathisia Rating Scale (BARS) Clinical Global Impression Severity Scale (CGI-S) Clinical Global Impression for Severity of Suicidality (CGI-SS) Columbia Suicide Scale

Epworth Sleepiness Scale (ESS)

Lab Assessments - 43 per subject

Screening Day -3: Pre-dose, 12, 24, 36, 48 and 60 hours Day 1: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120, 144, 168 hours Day 8: Pre-dose, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120, 144, 168 hours

ECGs

Screening Day 1: Pre-dose, 3, 5, 8 and 24 hr Day 8: Pre-dose, 3, 5, 8 and 24 hr

- Standard 12-lead ECGs
- Subjects need to be supine and at rest for ≥ 10 minutes prior to the ECG

Vitals

Screening Day 1: Pre-dose, 3, 5, 8 and 24 hr Day 8: Pre-dose, 3, 5, 8 and 24 hr

 Orthostatic (supine, sitting and standing) blood pressure and heart rate, body temperature and respiration rate. Orthostatic assessments are to be made after subjects have been in the supine position for at least 5 minutes and again after subjects have been standing for 2 minutes.

Key Elements:

- Inpatient
- Long Confinement
- High Enrollment